어댑티브 바이오테크놀로지스(ADPT)는 NAS에 상장된 Healthcare · Diagnostics & Research 기업입니다. 현재가 $28.61 (+0.21%), 시가총액 $2.08B.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
어댑티브 바이오테크놀로지스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
어댑티브 바이오테크놀로지스의 현재 주가는 $28.61 (+0.21%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
어댑티브 바이오테크놀로지스의 시가총액은 약 $2.08B입니다.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.